Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 7Recruiting 6Active not recruiting 6Terminated 2

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 2Gynecologic 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 11Neoplasms 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 4Endometrial Neoplasms 4Neuroendocrine Tumors 3Glioma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fanconi Anemia, Complementation Group D1 2Cholangiocarcinoma 2Uveal Melanoma 1Urogenital Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1SCLC,Extensive Stage 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1

Interventions

pembrolizumab 49Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 13Leucovorin 11Irinotecan 11Fluorouracil 11Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × olaparib × Clear all
NCT04585958 2026-06-05

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05898399 2026-05-01

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Artios Pharma Ltd

Phase 1/2 Recruiting
181 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06201234 2025-12-01

ELEMENT

GBG Forschungs GmbH

Phase 2 Recruiting
176 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05900895 2025-11-20

PHOEBE

Dartmouth-Hitchcock Medical Center

Phase 1 Recruiting
6 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02029001 2025-08-07

MOST plus

Centre Leon Berard

Phase 2 Recruiting
900 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡